Share this article
Share this article
SAN MATEO, Calif., May 4, 2021 /PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study. The Company anticipates enrolling the next higher dose cohort in the second part of May.
The VT3989 Phase 1 study is now open at centers in both the US and Australia (https://clinicaltrials.gov/ct2/show/NCT04665206) to evaluate the safety, tolerability, PK and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural malignant mesothelioma. The study is currently in dose escalation, to be followed by a dose expansion phase in which patients with
Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, closed a $30m Series C financing.
The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace.
The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.
Led by Sofie Qiao, Ph.D., President and Chief Executive Officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need. .
Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway
News provided by
Share this article
Share this article
SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C financing. The company anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP. The Series C financing was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. With the financing, Dr. Norman Zhou of Boxer Capital has joined the board of directors at Vivace.